ContraFect (NASDAQ:CFRX) released its quarterly earnings results on Wednesday. The biotechnology company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.28), MarketWatch Earnings reports.
CFRX stock traded up $0.02 during mid-day trading on Thursday, hitting $6.02. The company had a trading volume of 1,617 shares, compared to its average volume of 238,473. The firm has a market cap of $91.99 million, a PE ratio of 14.64 and a beta of 0.60. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.68 and a current ratio of 1.68. ContraFect has a 12 month low of $2.69 and a 12 month high of $13.40. The stock’s fifty day moving average price is $7.60 and its two-hundred day moving average price is $2.26.
Several research analysts recently weighed in on the stock. Maxim Group restated a “buy” rating and set a $22.00 price target on shares of ContraFect in a report on Thursday. ValuEngine cut shares of ContraFect from a “sell” rating to a “strong sell” rating in a report on Tuesday, March 3rd. Finally, Chardan Capital restated a “buy” rating and set a $15.00 price target on shares of ContraFect in a report on Monday, February 24th.
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza.
See Also: Trading Strategy Methods and Types
Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.